CN100515417C - Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis - Google Patents
Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis Download PDFInfo
- Publication number
- CN100515417C CN100515417C CNB2007100523521A CN200710052352A CN100515417C CN 100515417 C CN100515417 C CN 100515417C CN B2007100523521 A CNB2007100523521 A CN B2007100523521A CN 200710052352 A CN200710052352 A CN 200710052352A CN 100515417 C CN100515417 C CN 100515417C
- Authority
- CN
- China
- Prior art keywords
- meclofenoxate hydrochloride
- group
- head necrosis
- femoral head
- meclofenoxate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229960001637 meclofenoxate hydrochloride Drugs 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 230000017074 necrotic cell death Effects 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 208000007875 Femur Head Necrosis Diseases 0.000 claims description 20
- 238000002347 injection Methods 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 6
- 206010028851 Necrosis Diseases 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 9
- 241001484259 Lacuna Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010031264 Osteonecrosis Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004394 hip joint Anatomy 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 229960002800 prednisolone acetate Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- -1 2-(dimethylamino) ethyl Chemical group 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003442 meclofenoxate Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Group | n | Serum total cholesterol | Triglyceride |
The normal control group | 8 | 1.52±0.41 | 0.90±0.31 |
Model group | 8 | 4.60±0.88 ** | 3.84±0.82 ** |
The meclofenoxate hydrochloride group | 8 | 2.26±0.42 △△ | 1.42±0.29 △△ |
Group | n | The adipose cell proliferation degree | Medullary cavity osteonecrosis kitchen range |
The normal control group | 8 | A little | Do not have |
Model group | 8 | Obviously | Many |
The meclofenoxate hydrochloride group | 8 | A little | Few |
Group | n | The bone lacuna number |
The normal control group | 8 | 12.7±3.38 |
Model group | 8 | 33.5±7.83 ** |
The meclofenoxate hydrochloride group | 8 | 21.9±4.95 △△ |
Group | n | Femoral head bone density (g/cm 3) |
Normal control group model group meclofenoxate hydrochloride group | 8 8 8 | 0.878±0.148 0.839±0.186 ** 0.868±0.131 △△ |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100523521A CN100515417C (en) | 2007-06-01 | 2007-06-01 | Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100523521A CN100515417C (en) | 2007-06-01 | 2007-06-01 | Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101069683A CN101069683A (en) | 2007-11-14 |
CN100515417C true CN100515417C (en) | 2009-07-22 |
Family
ID=38897202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100523521A Active CN100515417C (en) | 2007-06-01 | 2007-06-01 | Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100515417C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332271A (en) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | Application of meclofenoxate hydrochloride in preparation of medicine for preventing or treating Parkinson's disease |
-
2007
- 2007-06-01 CN CNB2007100523521A patent/CN100515417C/en active Active
Non-Patent Citations (6)
Title |
---|
我们是怎样对氯酯醒进行二次开发的. 周伟昌.上海医药,第23卷第7期. 2002 |
我们是怎样对氯酯醒进行二次开发的. 周伟昌.上海医药,第23卷第7期. 2002 * |
注射用盐酸甲氯芬酯的临床应用. 张天锡.药学服务与研究,第5卷第4期. 2005 |
注射用盐酸甲氯芬酯的临床应用. 张天锡.药学服务与研究,第5卷第4期. 2005 * |
盐酸甲氯芬酯的药理作用和临床应用. 吕卫红.西北药学杂志,第19卷第1期. 2004 |
盐酸甲氯芬酯的药理作用和临床应用. 吕卫红.西北药学杂志,第19卷第1期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN101069683A (en) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Holding et al. | The correlation of RANK, RANKL and TNFα expression with bone loss volume and polyethylene wear debris around hip implants | |
CN105517536B (en) | The sustained-release composition of injectable and its for treatment of arthritis disease and ache related method | |
Meloni et al. | Failed vascularized fibular graft in treatment of osteonecrosis of the femoral head. A histopathological analysis | |
Wang et al. | The effect of bone marrow mesenchymal stem cell and nano‑hydroxyapatite/collagen I/poly‑L‑lactic acid scaffold implantation on the treatment of avascular necrosis of the femoral head in rabbits | |
Shao et al. | Stachydrine ameliorates the progression of intervertebral disc degeneration via the PI3K/Akt/NF-κB signaling pathway: in vitro and in vivo studies | |
Su et al. | Clearance of senescent cells by navitoclax (ABT263) rejuvenates UHMWPE-induced osteolysis | |
Liu et al. | Protection effect of curcumin for macrophage-involved polyethylene wear particle-induced inflammatory osteolysis by increasing the cholesterol efflux | |
CN100515417C (en) | Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis | |
CN106822377B (en) | Compound osteitis cataplasm patch and preparation method thereof | |
Yang et al. | Combination therapy with BMSCs‑exosomes and porous tantalum for the repair of femur supracondylar defects | |
Yang et al. | MiR-146 regulates the repair and regeneration of intervertebral nucleus pulposus cells via Notch1 pathway. | |
Torres-Torrillas et al. | Intra-osseous plasma rich in growth factors enhances cartilage and subchondral bone regeneration in rabbits with acute full thickness chondral defects: Histological assessment | |
Zhu et al. | Artesunate interfere in modulation of Foxp3 expression in synovial cells in collagen-induced arthritis rats | |
Guo et al. | Ginsenoside Rg1/ADSCs supplemented with hyaluronic acid as the matrix improves rabbit temporomandibular joint osteoarthrosis | |
CN101549177A (en) | Medicament coating applied to fixation screw in rachis, preparation method thereof and application thereof | |
JP6489487B2 (en) | Novel use for treating osteoarthritis with tetrapeptide-3 GEKG or pentapeptide-3 GEGF | |
Zhang et al. | Applications of digital technology for the morphological study of C3–C7 vertebral arch pedicle in children | |
CN104208056B (en) | The pharmaceutical use of L-dopa methyl ester hydrochloride in treatment Periprosthetic bone dissolves | |
CN103845329A (en) | Application of berberine in preparing product for preventing or treating obesity and related diseases or symptoms | |
CN106540246B (en) | Fibroblast vaccine and preparation method and application thereof | |
CN109793747A (en) | Application of the Vaccarin in terms of the drug of preparation prophylactic treatment bone dissolubility disease | |
CN109010909A (en) | The compound erythromycin bone cement of polymethyl methacrylate is used to prevent and treat the application of Periprosthetic bone dissolution and inflammatory reaction | |
Walters et al. | Cellular response to ectopically implanted silk sutures and osteopetrotic bone | |
CN108175769A (en) | Bolbostemma paniculatum glucoside A is preparing the application in treating medicine for treating rheumatoid arthritis | |
CN115005161B (en) | Construction method and application of mouse tail intervertebral disc degeneration model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Applicaiton of meclofenoxate hydrochloride in preparing medicine for treating femoral head necrosis Effective date of registration: 20110201 Granted publication date: 20090722 Pledgee: Bank of Communications Ltd Wuhan East Lake New Technology Development Zone sub branch Pledgor: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Registration number: 2011990000041 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180628 Granted publication date: 20090722 Pledgee: Bank of Communications Ltd Wuhan East Lake New Technology Development Zone sub branch Pledgor: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Registration number: 2011990000041 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180827 Address after: 519015, 2 floor, Heping industrial center, No. 209 Shihua Road, Zhuhai, Guangdong. Patentee after: Zhuhai morning Ann Pharmaceutical Co., Ltd. Address before: 430071 No. 100 purple sand road, Wuchang District, Wuhan, Hubei. Patentee before: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan Document name: Notification of Passing Examination on Formalities |